No connection

Search Results

ACRS vs PRTC

ACRS
Aclaris Therapeutics, Inc.
BEARISH
Price
$3.54
Market Cap
$428.6M
Sector
Healthcare
AI Confidence
87%
PRTC
PureTech Health plc
NEUTRAL
Price
$18.30
Market Cap
$445.5M
Sector
Healthcare
AI Confidence
75%

Valuation

P/E Ratio
ACRS
--
PRTC
10.7
Forward P/E
ACRS
-4.42
PRTC
-36.6
P/B Ratio
ACRS
4.14
PRTC
1.17
P/S Ratio
ACRS
54.77
PRTC
69.7
EV/EBITDA
ACRS
-4.57
PRTC
-36.48

Profitability

Gross Margin
ACRS
0.0%
PRTC
0.0%
Operating Margin
ACRS
-1724.63%
PRTC
-2589.52%
Profit Margin
ACRS
0.0%
PRTC
792.96%
ROE
ACRS
-50.2%
PRTC
9.44%
ROA
ACRS
-24.32%
PRTC
-12.95%

Growth

Revenue Growth
ACRS
-85.9%
PRTC
542.7%
Earnings Growth
ACRS
--
PRTC
--

Financial Health

Debt/Equity
ACRS
0.02
PRTC
0.44
Current Ratio
ACRS
3.36
PRTC
8.49
Quick Ratio
ACRS
3.36
PRTC
8.35

Dividends

Dividend Yield
ACRS
--
PRTC
--
Payout Ratio
ACRS
0.0%
PRTC
0.0%

AI Verdict

ACRS BEARISH

ACRS exhibits severe financial distress despite a strong analyst consensus, as evidenced by a Piotroski F-Score of 1/9 indicating extreme weakness in operational and financial health. The company reports negative profitability across all key margins, with a staggering -1724.63% operating margin and a -50.20% ROE, signaling deep operational inefficiency. Although the debt-to-equity ratio is low (0.02) and liquidity is strong (current ratio 3.36), the company's revenue has collapsed by 85.9% YoY, and it continues to burn cash with no free cash flow. The absence of a Graham Number and intrinsic value estimate underscores the lack of a reliable valuation anchor, while the stock trades at an inflated Price/Sales of 54.77, suggesting extreme speculative pricing. Despite a recent 126.9% 1-year return, the underlying fundamentals remain critically deteriorating.

Strengths
Strong liquidity with current and quick ratios of 3.36
Low debt-to-equity ratio of 0.02, indicating minimal leverage risk
Analyst consensus of 'strong_buy' with a target price of $8.29
Risks
Piotroski F-Score of 1/9 indicates severe financial distress and operational failure
Revenue declined 85.9% YoY, signaling business contraction
Negative operating margin (-1724.63%) and ROE (-50.20%) reflect deep unprofitability
PRTC NEUTRAL

PRTC presents a contradictory financial profile with a stable Piotroski F-Score of 5/9 and a strong liquidity position (Current Ratio 8.49), yet suffers from severe operational inefficiency. While the Graham Number of $24.47 suggests defensive value, the growth-based intrinsic value of $11.90 and a negative forward P/E indicate significant future earnings risk. The massive discrepancy between the reported profit margin (792.96%) and operating margin (-2589.52%) suggests the company is relying on non-operating gains rather than core business profitability. Short-term price momentum is positive, but long-term performance remains deeply depressed.

Strengths
Exceptional short-term liquidity with a Current Ratio of 8.49
Low leverage with a Debt/Equity ratio of 0.44
Explosive year-over-year revenue growth of 542.70%
Risks
Catastrophic operating margins (-2589.52%) indicating high cash burn
Negative forward P/E suggests expected losses in the coming year
Extremely high Price-to-Sales ratio (69.70) indicating overvaluation relative to revenue

Compare Another Pair

ACRS vs PRTC: Head-to-Head Comparison

This page compares Aclaris Therapeutics, Inc. (ACRS) and PureTech Health plc (PRTC) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile